Find investors
← Back to all investors
John Maldonado
ResearchedAngel Investors

John Maldonado

Managing Partner

Angel InvestorsSeed Round
Pitch John

Get their honest, personalized take on your startup.

Sign in to pitch John

At a glance

Full Name
John Maldonado
Title
Managing Partner & Co-Head of North America
Firm
Advent International
Firm Type
Global private equity (buyout & growth) — *not an angel investor; the "Angel Investors / Seed Round" label in the stub is incorrect*
Investment Stage
Buyouts, growth equity, and control investments in established companies (large-cap private equity)
Check Size
Large-cap equity checks — Advent typically deploys hundreds of millions to over a billion dollars per deal (specific per-deal figures not publicly disclosed)
Target Company Profile
Established, market-leading companies with strong management teams; control buyouts and platform investments
Sector Focus
Healthcare, and Business & Financial Services
Geographic Focus
North America (United States), within Advent's global platform
Location
Boston, Massachusetts

Background

John Maldonado is a Managing Partner at Advent International and serves as Co-Head of North America, based in the firm's Boston headquarters. He joined Advent in 2006 and has spent roughly two decades focused on control buyouts in the healthcare and business & financial services sectors. Over his career he has advised on 25 investments, 22 of them at Advent, and he also serves on Advent's leadership committees (reported as Co-Chair of the firm's Executive Committee).

Before Advent, Maldonado built a career across strategy consulting and private equity. He began as a consultant at The Parthenon Group, a leading strategy consulting firm, and then worked in private equity at Bain Capital and Parthenon Capital before moving to Advent.

He was educated at Dartmouth College, where he earned a BA, summa cum laude, and at Harvard Business School, where he received an MBA with high distinction as a Baker Scholar (a distinction reserved for the top of the graduating class).

In his current role he sits on the boards of several Advent portfolio companies and healthcare-focused entities, and he is a public voice for the firm — for example, appearing on CNBC's "Closing Bell" in early 2025 to discuss Advent's outlook on M&A, IPO markets, interest rates, and AI-driven opportunities.

Investment Thesis & Focus

  • Invests through control buyouts and growth investments in established, market-leading businesses — this is large-cap private equity, not seed/angel investing.
  • Sector concentration: healthcare (services, pharma/biopharma, healthcare technology) and business & financial services.
  • Emphasizes partnering closely with strong management teams — he has stated that "great deals are born from great talent."
  • Credits Advent's privately-owned partnership structure for allowing the firm to focus on building exceptional, durable businesses alongside management rather than chasing short-term growth metrics.
  • Geographic remit centers on North America within Advent's global sector-focused model.

Notable Investments

  • Waystar (formerly Iodine Software) — healthcare payments/revenue-cycle technology; Advent-backed, later a public company. Maldonado held a board seat at Iodine Software.
  • Genoa Healthcare — pharmacy services provider serving behavioral health populations.
  • Syneos Health — biopharmaceutical outsourcing / clinical and commercial services organization.
  • Simtra BioPharma Solutions — sterile contract development and manufacturing (CDMO) carve-out.
  • Bharat Serums and Vaccines (BSV) — Indian biopharmaceutical company (women's health and critical care).
  • Cohance Lifesciences (formerly Suven) — pharma CDMO platform in India.
  • Apollo 24/7 / Apollo-related healthcare — digital healthcare investment.
  • Felix — Advent-listed investment among his healthcare deals.
  • AccentCare — home health and hospice services provider; Maldonado has served as a director (since ~2019).
  • RxBenefits — pharmacy benefits optimization company; Maldonado has served as a director (since ~2021).

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.